Neuralink launches VOICE trial for speech decoding — translating vocal intention into text for ALS patients
Summary
Neuralink launched the VOICE trial — a clinical study translating intended voice/speech into text output — referenced in Neurotech Notables #51 (March 2026). The VOICE trial represents Neuralink's expansion beyond cursor control and typing BCI toward speech decoding, competing directly with Paradromics (Connect-One, speech as primary endpoint) and Synchron (speech restoration as a secondary endpoint). By encoding speech intention from motor cortex signals, the VOICE trial aims to restore natural communication speed for ALS and SCI patients with speech impairment.
Why it matters
Neuralink launching a speech decoding trial alongside their existing PRIME cursor-control trial means the company is simultaneously pursuing two distinct BCI communication modalities — typed cursor control and speech restoration. Running both trials in parallel generates competitive data against Paradromics (200+ bps speech focus) and enables Neuralink to select the most clinically effective communication approach for their FDA PMA submission.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial